We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dose adjusted- EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
- Authors
Chihara, Dai; Westin, Jason R.; Miranda, Roberto N.; Cheah, Chan Y.; Oki, Yasuhiro; Turturro, Francesco; Romaguera, Jorge E.; Neelapu, Sattva S.; Nastoupil, Lorreta J.; Fayad, Luis E.; Rodriguez, M. Alma; Fowler, Nathan H.; Orlowski, Robert Z.; Wang, Michael; Hagemeister, Fredrick B.; Medeiros, L. Jeffrey; Fanale, Michelle A.
- Abstract
The article presents a study which analyzed patients diagnosed with gray-zone lymphoma (GZL) at the University of Texas MD Anderson Cancer Center in Houston, Texas. Topics discussed include characteristics of patients with GZL, longer progression-free survival (PFS) found in patients with mediastinal GZL, and indication that dose-adjusted etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (DA-EPOCH-R) may improve outcome for patients with GZL.
- Subjects
LYMPHOMAS; ETOPOSIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE; PREDNISONE; RITUXIMAB; PATIENTS; THERAPEUTICS
- Publication
British Journal of Haematology, 2017, Vol 179, Issue 3, p503
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.14226